Cancer Pharmacology

Discovering the cellular and molecular causes of cancer, as well as identifying and creating new anti-cancer targets and treatment approaches, are the main goals of pharmacology. Our work creates a link between the disciplines of radiation biology, clinical pharmacology, biochemical pharmacology, and molecular carcinogenesis. The Roget Cancer Center, an NCI-designated comprehensive cancer centre, and the Pharmacology Department work closely together on our research activities.

Genetic and epigenetic processes that result in neoplastic transformation characterise the pathologic state known as cancer. Inadequate diagnosis, poor prognosis causing recurrence, and anticancer drug resistance to existing treatment regimens are the main obstacles to cancer prevention and treatment. However, it is extremely difficult for medications to target important pathways that are unique to cancer cells, which has led to low potency, poor target or isoform or kinase selectivity by the present pharmaceuticals or molecules in clinical trials. Off-target effects are also extremely challenging to ignore due to most existing medicines' poor pharmacokinetics and low durability.

    Related Conference of Cancer Pharmacology

    January 03-04, 2023

    International Congress on HIV-Aids and STD's

    London, UK
    February 15-16, 2023

    11th World Summit on Immunology and Immunotherapy

    Zurich, Switzerland
    February 20-21, 2023

    Global Summit on SARS-CoV-2 virus

    Madrid, Spain
    February 21-22, 2023

    4th European Congress on Hematology

    Zurich, Switzerland
    May 24-25, 2023

    37th International Conference on Immunology

    Vienna, Austria

    Cancer Pharmacology Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in